Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
For hemophilia A (congenital factor VIII deficiency) with or without factor VIII…. Sold as Hemlibra. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 1 application for Emicizumab (sold as Hemlibra), first approved Nov 16, 2017, with 2 new uses approved and 0 published complete response letters.
First approved in Japan 4 months after the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Hemlibra s.c.Drugs with a new indication and a new dosage for the control of bleeding tendency in patients with acquired hemophilia A. · Chugai Pharmaceutical Co., Ltd. · Jun 20, 2022
Hemlibra s.c.Drugs with a new dosage indicated for the control of bleeding tendency in patients with congenital blood coagulation factor VIII deficiency with blood… · Chugai Pharmaceutical Co., Ltd. · Dec 21, 2018
Hemlibra s.c.Drugs with a new additional indication and a new dosage for the control of bleeding tendency in patients with blood coagulation factor VIII deficiency… · Chugai Pharmaceutical Co., Ltd. · Dec 21, 2018
Hemlibra s.c., new ingredientDrugs with a new active ingredient indicated for the control of bleeding tendency in patients with congenital blood coagulation factor VIII deficiency with… · Chugai Pharmaceutical Co., Ltd. · Mar 23, 2018 · Review report
Clinical Trials
24 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA